annalsofneurology8k.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): November 17, 2010
 
Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
  
000-50513
  
13-3831168
(State or other jurisdiction
  
(Commission
  
(I.R.S. Employer
of incorporation)
  
File Number)
  
Identification No.)
         
   
15 Skyline Drive, Hawthorne, NY
  
10532
   
(Address of principal executive offices)
  
(Zip Code)
         
Registrant’s telephone number, including area code:  (914) 347-4300
 
Not Applicable
Former name or former address, if changed since last report
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 
 
 

Item 8.01 Other Events

On November 17, 2010, Acorda Therapeutics, Inc. issued a press release announcing that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis were published in the October 2010 edition of Annals of Neurology.  A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.                    Description

99.1                                 Press Release dated November 17, 2010.

 
 
 

SIGNATURES
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Acorda Therapeutics, Inc.
     
November 17, 2010
By:
/s/ David Lawrence
   
Name: David Lawrence
   
Title: Chief Financial Officer

 
 
 

Exhibit Index



Exhibit No.                                                                         Description


99.1                                                                                     Press Release dated November 17, 2010